Effect of ursodeoxycholic acid treatment on the expression and function of multidrug resistance-associated protein 2 in rat intestine
Effect of ursodeoxycholic acid (UDCA) treatment on the expression and function of intestinal multidrug resistance-associated protein (Mrp) 2 was examined in rats. When rats were orally administered 0.5% UDCA solution for 6 days, mRNA and protein levels of Mrp2 in the intestine were increased about t...
Gespeichert in:
| Veröffentlicht in: | Journal of pharmaceutical sciences 2009-08, Vol.98 (8), p.2822-2831 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 2831 |
|---|---|
| container_issue | 8 |
| container_start_page | 2822 |
| container_title | Journal of pharmaceutical sciences |
| container_volume | 98 |
| creator | Yumoto, Ryoko Hamada, Shota Okada, Kaori Kato, Yuki Ikehata, Mika Nagai, Junya Takano, Mikihisa |
| description | Effect of ursodeoxycholic acid (UDCA) treatment on the expression and function of intestinal multidrug resistance-associated protein (Mrp) 2 was examined in rats. When rats were orally administered 0.5% UDCA solution for 6 days, mRNA and protein levels of Mrp2 in the intestine were increased about twofold compared with those in untreated rats. In in vitro everted sac study, Mrp2-mediated efflux of 2,4-dinitrophenyl-S-glutathione (DNP-SG) to the mucosal surface was shown to be increased by UDCA treatment. In vivo intestinal exsorption clearance of DNP-SG was also increased by UDCA treatment. In addition, in situ intestinal absorption of methotrexate, a substrate of Mrp2, was decreased by the treatment. These results indicate that the expression and function of intestinal Mrp2 is up-regulated by oral administration of UDCA. © 2008 Wiley-Liss, Inc. and the American Pharmacists Association J Pharm Sci 98:2822–2831, 2009 |
| doi_str_mv | 10.1002/jps.21628 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_733361204</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0022354916330490</els_id><sourcerecordid>733361204</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4368-efb9137ad4bd33933d7f983ef14d6cec7888509a3bb67fce6f8f93416a6878ec3</originalsourceid><addsrcrecordid>eNp1ks9u1DAQxiMEokvhwAsgXxDikNaOE9s5olJaUFWQKO3Rcuwxdcmfre3A7gPw3kzJUi5w8Wjk38w3_sZF8ZzRA0ZpdXizTgcVE5V6UKxYU9FSUCYfFiu8q0re1O1e8SSlG0qpoE3zuNhjLRWSt_Wq-HnsPdhMJk_mmCYH02Zrr6c-WGJscCRHMHmAEYmR5GsgsFlHSClgakZH_DzafJdgg2Huc3Bx_kqQCCmb0UJpUppsMBkcWccpQxhJRfCIJmPIkHIY4WnxyJs-wbNd3C--vDu-ODotzz6evD96c1bamgtVgu9axqVxdec4bzl30reKg2e1ExasVEo1tDW864T0FoRXvuU1E0YoqcDy_eLV0hdHuZ1RWw8hWeh7M8I0Jy0554JVtEby9ULaOKUUwet1DIOJW82ovjNdo-n6t-nIvth1nbsB3F9y5zICL3eASdb0PqIzId1zFZOtwo0hd7hwP0IP2_8r6g-fPv-RLpcKtBs29xUmftMoLRt9dX6iT6_q6uL88q2-RJ4vPKDL3wNEnWwA3JMLEb-BdlP4xwN_AcXLvJw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>733361204</pqid></control><display><type>article</type><title>Effect of ursodeoxycholic acid treatment on the expression and function of multidrug resistance-associated protein 2 in rat intestine</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><source>Alma/SFX Local Collection</source><creator>Yumoto, Ryoko ; Hamada, Shota ; Okada, Kaori ; Kato, Yuki ; Ikehata, Mika ; Nagai, Junya ; Takano, Mikihisa</creator><creatorcontrib>Yumoto, Ryoko ; Hamada, Shota ; Okada, Kaori ; Kato, Yuki ; Ikehata, Mika ; Nagai, Junya ; Takano, Mikihisa</creatorcontrib><description>Effect of ursodeoxycholic acid (UDCA) treatment on the expression and function of intestinal multidrug resistance-associated protein (Mrp) 2 was examined in rats. When rats were orally administered 0.5% UDCA solution for 6 days, mRNA and protein levels of Mrp2 in the intestine were increased about twofold compared with those in untreated rats. In in vitro everted sac study, Mrp2-mediated efflux of 2,4-dinitrophenyl-S-glutathione (DNP-SG) to the mucosal surface was shown to be increased by UDCA treatment. In vivo intestinal exsorption clearance of DNP-SG was also increased by UDCA treatment. In addition, in situ intestinal absorption of methotrexate, a substrate of Mrp2, was decreased by the treatment. These results indicate that the expression and function of intestinal Mrp2 is up-regulated by oral administration of UDCA. © 2008 Wiley-Liss, Inc. and the American Pharmacists Association J Pharm Sci 98:2822–2831, 2009</description><identifier>ISSN: 0022-3549</identifier><identifier>EISSN: 1520-6017</identifier><identifier>DOI: 10.1002/jps.21628</identifier><identifier>PMID: 19067394</identifier><identifier>CODEN: JPMSAE</identifier><language>eng</language><publisher>Hoboken: Elsevier Inc</publisher><subject>Animals ; Biological and medical sciences ; DNP-SG ; Gene Expression Regulation - drug effects ; General pharmacology ; Intestinal Mucosa - drug effects ; Intestinal Mucosa - metabolism ; Intestinal Mucosa - physiology ; intestine ; Jejunum - drug effects ; Jejunum - metabolism ; Male ; Medical sciences ; methotrexate ; Mrp2 ; Multidrug Resistance-Associated Proteins - biosynthesis ; Multidrug Resistance-Associated Proteins - genetics ; Multidrug Resistance-Associated Proteins - physiology ; Pharmaceutical technology. Pharmaceutical industry ; Pharmacology. Drug treatments ; Rats ; Rats, Wistar ; Treatment Outcome ; UDCA ; Ursodeoxycholic Acid - pharmacology</subject><ispartof>Journal of pharmaceutical sciences, 2009-08, Vol.98 (8), p.2822-2831</ispartof><rights>2008 Wiley Liss, Inc.</rights><rights>Copyright © 2008 Wiley‐Liss, Inc.</rights><rights>2009 INIST-CNRS</rights><rights>Copyright 2009 Wiley-Liss, Inc.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4368-efb9137ad4bd33933d7f983ef14d6cec7888509a3bb67fce6f8f93416a6878ec3</citedby><cites>FETCH-LOGICAL-c4368-efb9137ad4bd33933d7f983ef14d6cec7888509a3bb67fce6f8f93416a6878ec3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fjps.21628$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fjps.21628$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=21798017$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19067394$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Yumoto, Ryoko</creatorcontrib><creatorcontrib>Hamada, Shota</creatorcontrib><creatorcontrib>Okada, Kaori</creatorcontrib><creatorcontrib>Kato, Yuki</creatorcontrib><creatorcontrib>Ikehata, Mika</creatorcontrib><creatorcontrib>Nagai, Junya</creatorcontrib><creatorcontrib>Takano, Mikihisa</creatorcontrib><title>Effect of ursodeoxycholic acid treatment on the expression and function of multidrug resistance-associated protein 2 in rat intestine</title><title>Journal of pharmaceutical sciences</title><addtitle>J. Pharm. Sci</addtitle><description>Effect of ursodeoxycholic acid (UDCA) treatment on the expression and function of intestinal multidrug resistance-associated protein (Mrp) 2 was examined in rats. When rats were orally administered 0.5% UDCA solution for 6 days, mRNA and protein levels of Mrp2 in the intestine were increased about twofold compared with those in untreated rats. In in vitro everted sac study, Mrp2-mediated efflux of 2,4-dinitrophenyl-S-glutathione (DNP-SG) to the mucosal surface was shown to be increased by UDCA treatment. In vivo intestinal exsorption clearance of DNP-SG was also increased by UDCA treatment. In addition, in situ intestinal absorption of methotrexate, a substrate of Mrp2, was decreased by the treatment. These results indicate that the expression and function of intestinal Mrp2 is up-regulated by oral administration of UDCA. © 2008 Wiley-Liss, Inc. and the American Pharmacists Association J Pharm Sci 98:2822–2831, 2009</description><subject>Animals</subject><subject>Biological and medical sciences</subject><subject>DNP-SG</subject><subject>Gene Expression Regulation - drug effects</subject><subject>General pharmacology</subject><subject>Intestinal Mucosa - drug effects</subject><subject>Intestinal Mucosa - metabolism</subject><subject>Intestinal Mucosa - physiology</subject><subject>intestine</subject><subject>Jejunum - drug effects</subject><subject>Jejunum - metabolism</subject><subject>Male</subject><subject>Medical sciences</subject><subject>methotrexate</subject><subject>Mrp2</subject><subject>Multidrug Resistance-Associated Proteins - biosynthesis</subject><subject>Multidrug Resistance-Associated Proteins - genetics</subject><subject>Multidrug Resistance-Associated Proteins - physiology</subject><subject>Pharmaceutical technology. Pharmaceutical industry</subject><subject>Pharmacology. Drug treatments</subject><subject>Rats</subject><subject>Rats, Wistar</subject><subject>Treatment Outcome</subject><subject>UDCA</subject><subject>Ursodeoxycholic Acid - pharmacology</subject><issn>0022-3549</issn><issn>1520-6017</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2009</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1ks9u1DAQxiMEokvhwAsgXxDikNaOE9s5olJaUFWQKO3Rcuwxdcmfre3A7gPw3kzJUi5w8Wjk38w3_sZF8ZzRA0ZpdXizTgcVE5V6UKxYU9FSUCYfFiu8q0re1O1e8SSlG0qpoE3zuNhjLRWSt_Wq-HnsPdhMJk_mmCYH02Zrr6c-WGJscCRHMHmAEYmR5GsgsFlHSClgakZH_DzafJdgg2Huc3Bx_kqQCCmb0UJpUppsMBkcWccpQxhJRfCIJmPIkHIY4WnxyJs-wbNd3C--vDu-ODotzz6evD96c1bamgtVgu9axqVxdec4bzl30reKg2e1ExasVEo1tDW864T0FoRXvuU1E0YoqcDy_eLV0hdHuZ1RWw8hWeh7M8I0Jy0554JVtEby9ULaOKUUwet1DIOJW82ovjNdo-n6t-nIvth1nbsB3F9y5zICL3eASdb0PqIzId1zFZOtwo0hd7hwP0IP2_8r6g-fPv-RLpcKtBs29xUmftMoLRt9dX6iT6_q6uL88q2-RJ4vPKDL3wNEnWwA3JMLEb-BdlP4xwN_AcXLvJw</recordid><startdate>200908</startdate><enddate>200908</enddate><creator>Yumoto, Ryoko</creator><creator>Hamada, Shota</creator><creator>Okada, Kaori</creator><creator>Kato, Yuki</creator><creator>Ikehata, Mika</creator><creator>Nagai, Junya</creator><creator>Takano, Mikihisa</creator><general>Elsevier Inc</general><general>Wiley Subscription Services, Inc., A Wiley Company</general><general>Wiley</general><general>American Pharmaceutical Association</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>200908</creationdate><title>Effect of ursodeoxycholic acid treatment on the expression and function of multidrug resistance-associated protein 2 in rat intestine</title><author>Yumoto, Ryoko ; Hamada, Shota ; Okada, Kaori ; Kato, Yuki ; Ikehata, Mika ; Nagai, Junya ; Takano, Mikihisa</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4368-efb9137ad4bd33933d7f983ef14d6cec7888509a3bb67fce6f8f93416a6878ec3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2009</creationdate><topic>Animals</topic><topic>Biological and medical sciences</topic><topic>DNP-SG</topic><topic>Gene Expression Regulation - drug effects</topic><topic>General pharmacology</topic><topic>Intestinal Mucosa - drug effects</topic><topic>Intestinal Mucosa - metabolism</topic><topic>Intestinal Mucosa - physiology</topic><topic>intestine</topic><topic>Jejunum - drug effects</topic><topic>Jejunum - metabolism</topic><topic>Male</topic><topic>Medical sciences</topic><topic>methotrexate</topic><topic>Mrp2</topic><topic>Multidrug Resistance-Associated Proteins - biosynthesis</topic><topic>Multidrug Resistance-Associated Proteins - genetics</topic><topic>Multidrug Resistance-Associated Proteins - physiology</topic><topic>Pharmaceutical technology. Pharmaceutical industry</topic><topic>Pharmacology. Drug treatments</topic><topic>Rats</topic><topic>Rats, Wistar</topic><topic>Treatment Outcome</topic><topic>UDCA</topic><topic>Ursodeoxycholic Acid - pharmacology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Yumoto, Ryoko</creatorcontrib><creatorcontrib>Hamada, Shota</creatorcontrib><creatorcontrib>Okada, Kaori</creatorcontrib><creatorcontrib>Kato, Yuki</creatorcontrib><creatorcontrib>Ikehata, Mika</creatorcontrib><creatorcontrib>Nagai, Junya</creatorcontrib><creatorcontrib>Takano, Mikihisa</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of pharmaceutical sciences</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Yumoto, Ryoko</au><au>Hamada, Shota</au><au>Okada, Kaori</au><au>Kato, Yuki</au><au>Ikehata, Mika</au><au>Nagai, Junya</au><au>Takano, Mikihisa</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effect of ursodeoxycholic acid treatment on the expression and function of multidrug resistance-associated protein 2 in rat intestine</atitle><jtitle>Journal of pharmaceutical sciences</jtitle><addtitle>J. Pharm. Sci</addtitle><date>2009-08</date><risdate>2009</risdate><volume>98</volume><issue>8</issue><spage>2822</spage><epage>2831</epage><pages>2822-2831</pages><issn>0022-3549</issn><eissn>1520-6017</eissn><coden>JPMSAE</coden><abstract>Effect of ursodeoxycholic acid (UDCA) treatment on the expression and function of intestinal multidrug resistance-associated protein (Mrp) 2 was examined in rats. When rats were orally administered 0.5% UDCA solution for 6 days, mRNA and protein levels of Mrp2 in the intestine were increased about twofold compared with those in untreated rats. In in vitro everted sac study, Mrp2-mediated efflux of 2,4-dinitrophenyl-S-glutathione (DNP-SG) to the mucosal surface was shown to be increased by UDCA treatment. In vivo intestinal exsorption clearance of DNP-SG was also increased by UDCA treatment. In addition, in situ intestinal absorption of methotrexate, a substrate of Mrp2, was decreased by the treatment. These results indicate that the expression and function of intestinal Mrp2 is up-regulated by oral administration of UDCA. © 2008 Wiley-Liss, Inc. and the American Pharmacists Association J Pharm Sci 98:2822–2831, 2009</abstract><cop>Hoboken</cop><pub>Elsevier Inc</pub><pmid>19067394</pmid><doi>10.1002/jps.21628</doi><tpages>10</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0022-3549 |
| ispartof | Journal of pharmaceutical sciences, 2009-08, Vol.98 (8), p.2822-2831 |
| issn | 0022-3549 1520-6017 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_733361204 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete; Alma/SFX Local Collection |
| subjects | Animals Biological and medical sciences DNP-SG Gene Expression Regulation - drug effects General pharmacology Intestinal Mucosa - drug effects Intestinal Mucosa - metabolism Intestinal Mucosa - physiology intestine Jejunum - drug effects Jejunum - metabolism Male Medical sciences methotrexate Mrp2 Multidrug Resistance-Associated Proteins - biosynthesis Multidrug Resistance-Associated Proteins - genetics Multidrug Resistance-Associated Proteins - physiology Pharmaceutical technology. Pharmaceutical industry Pharmacology. Drug treatments Rats Rats, Wistar Treatment Outcome UDCA Ursodeoxycholic Acid - pharmacology |
| title | Effect of ursodeoxycholic acid treatment on the expression and function of multidrug resistance-associated protein 2 in rat intestine |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-09T07%3A07%3A47IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effect%20of%20ursodeoxycholic%20acid%20treatment%20on%20the%20expression%20and%20function%20of%20multidrug%20resistance-associated%20protein%202%20in%20rat%20intestine&rft.jtitle=Journal%20of%20pharmaceutical%20sciences&rft.au=Yumoto,%20Ryoko&rft.date=2009-08&rft.volume=98&rft.issue=8&rft.spage=2822&rft.epage=2831&rft.pages=2822-2831&rft.issn=0022-3549&rft.eissn=1520-6017&rft.coden=JPMSAE&rft_id=info:doi/10.1002/jps.21628&rft_dat=%3Cproquest_cross%3E733361204%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=733361204&rft_id=info:pmid/19067394&rft_els_id=S0022354916330490&rfr_iscdi=true |